Literature DB >> 9186041

Role of Ca+2 and other second messengers in excitatory amino acid receptor mediated neurodegeneration: clinical perspectives.

A Schousboe1, B Belhage, A Frandsen.   

Abstract

Neurodegeneration associated with neurological disorders such as epilepsy, Huntington's Chorea, Alzheimer's disease, and olivoponto cerebellar atrophy or with energy failure such as ischemia, hypoxia, and hypoglycemia proceeds subsequent to overexposure of neurons to excitatory amino acids of which glutamate and aspartate may be quantitatively the most important. The toxic action of glutamate and aspartate is mediated through activation of glutamate receptors of the N-methyl-D-aspartate (NMDA) and non-NMDA subtypes. Antagonists for these receptors can act as neuroprotectants both in in vitro model systems (e.g., cultured neurons) and in vivo. Activation of receptors leads to an increase in the intracellular Ca++ concentration and also to an increase in other second messengers such as cGMP. Thus, Ca++ channel antagonists may have neuroprotective action under certain conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186041

Source DB:  PubMed          Journal:  Clin Neurosci        ISSN: 1065-6766


  4 in total

Review 1.  Neuropsychological functioning associated with high-altitude exposure.

Authors:  Javier Virués-Ortega; Gualberto Buela-Casal; Eduardo Garrido; Bernardino Alcázar
Journal:  Neuropsychol Rev       Date:  2004-12       Impact factor: 7.444

2.  Concentration dependent actions of glucocorticoids on neuronal viability and survival.

Authors:  István M Abrahám; Peter Meerlo; Paul G M Luiten
Journal:  Dose Response       Date:  2006-06-20       Impact factor: 2.658

3.  Lipopolysaccharide-Induced Apoptosis of Astrocytes: Therapeutic Intervention by Minocycline.

Authors:  Arpita Sharma; Nisha Patro; Ishan K Patro
Journal:  Cell Mol Neurobiol       Date:  2015-07-19       Impact factor: 5.046

Review 4.  Dantrolene, a treatment for Alzheimer disease?

Authors:  Li Liang; Huafeng Wei
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.